Biopharmaceutical firm VistaGen Q1 net loss widens

Vistagen Therapeutics

07/08/2025 21:46

Overview

VistaGen fiscal Q1 2026 net loss widens to $15.1 mln from $10.7 mln

R&D expenses rose to $11.7 mln, driven by PALISADE Program for fasedienol

Topline results for PALISADE-3 expected in Q4 2025, PALISADE-4 in H1 2026

Outlook

Vistagen expects PALISADE-3 Phase 3 results in Q4 2025

Topline results for PALISADE-4 expected in H1 2026

Company preparing Phase 2 development for PH80 in menopausal hot flashes

Vistagen planning further Phase 2 development for itruvone in MDD

Result Drivers

R&D EXPENSES - Increase driven by PALISADE Program for fasedienol in social anxiety disorder

PIPELINE ADVANCEMENT - Continued development of intranasal pherine product candidates across psychiatry, women's health, and cancer supportive care

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.47
Q1 Net Income
-$15.10 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $12.00, about 75.3% above its August 6 closing price of $2.97

Press Release: ID:nBwc8PDq7a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)